CD8A and neoplasm: The inhibition of immunosuppressive TAMCs and increased TIL infiltration achieved by RANKL/RANK blockade complements the reversal of CD8+ T‐cell dysfunction resulting from PD‐1 blockade, leading to an enhanced anti‐tumor effect.